Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Lenalidomide with DA-EPOCH-R in R/R DLBCL
NCT02142049Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- May 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Pharmacyclics. Started May 2014; status: completed.
02
Drugs
ibrutiniblenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02142049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142049.